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Supplementary Tables and Figures 
Table S1: Use/consumption data of anticancer drugs in hospitals in NW England as well as selected studies 








































1300 (9.8) 610 (4.3) 1900 (15.8) 1300 (7.1) 1400 (2.6) 71000 (84.5) 
12918(310-
71000) 310 610 
Chlorambucil 12 (0.1) - 10 (0.1) - 12 (0.0) - 6 (10-12) 8 - 
Melphalan 1 (0.0) - 20 (0.2) - 1 (0.0) - 4 (1-20) 5 - 
Ifosfamide 
150 (1.1) - - - 120 (0.2) 1000 (1.2) 
423 (120-
1000) 100 450 
Bendamustine - - 1 (0.0) - 91 (0.2) - 15 (1-91) - - 
Busulfan <1 - 30 (0.2) - - - 5 (<1-30) - - 
Treosulfan 
200 (1.5) 860 (6.0) 400 (3.3) 100 (0.5) - - 
260 (100-
860) - - 
Carmustine - - 6 (0.0) - - - 1 (6) 2 - 
Lomustine - - 6 (0.0) - - 42 (0.0) 8 (6-42) 3 - 
Temozolomide 
- 120 (0.8) - - - 900 (1.1) 
170 (120-
900) 54 - 
Dacarbazine 
83 (0.6) 36 (0.3) 64 (0.5) 60 (0.3) 50 (0.1) 460 (0.5) 
126 (36-
460) 29 - 
Methotrexate  12 (0.1) - 130 (1.1) 7 (0.0) 260 (0.5) 900 (1.1) 218 (7- 75 410 
900) 
Pemetrexed  
160 (1.2) 150 (1.1) 130 (1.1) 140 (0.8) 35 (0.1) 870 (1.0) 
248 (35-
870) 37 - 
Mercaptopurine 16 (0.1) - 26 (0.2) - 90 (0.2) - 22 (16-90) 95 - 
Tioguanine - - - - 2 (0.0) - <1 (2) 2 - 
Cladribine <1 1 (0.0) <1 - <1 - <1 (<1-1) - - 
Fludarabine 11 (0.1) - 9 (0.1) - 16 (0.0) - 6 (9-16) 6 6 
Cytarabine 
8 (0.1) - 940 (7.8) 64 (0.4) 970 (1.8) - 
330 (8-




(21.8) 1800 (14.9) 790 (4.3) 1800 (3.4) 13000 (1.5) 
3832 (790-
13000) 1700 3100 




(16.1) 860 (7.1) 1600 (8.8) 110 (0.2) 6800 (0.8) 
2162 (110-












230000) 5100 - 
Azacitidine 18 (0.1) - 11 (0.1) 28 (0.2) 17 (0.0) - 12 (11-28) - - 
Vinblastine 2 (0.0) - 2 (0.0) <1 1 (0.0) - 1 (<1-2) 1 - 
Vincristine 1 (0.0) 1 (0.0) 1 (0.0) <1 1 (0.0) <1 1 (<1-1) ˂1 1 
Vinorelbine 13 (0.1) 19 (0.1) 45 (0.4) - 1 (0.0) 220 (0.0) 50 (1-220) 13 - 
Etoposide 
190 (1.4) 90 (0.6) 210 (1.7) 3 (0.0) 38 (0.1) 700 (0.1) 
205 (3-
700) 41 110 
Paclitaxel 
35 (0.3) 200 (1.4) 39 (0.3) 57 (0.3) 140 (0.3) 390 (0.0) 
144 (35-
390) 39 79 
Docetaxel 
58 (0.4) 74 (0.5) 44 (0.4) 53 (0.3) 43 (0.1) 260 (0.0) 
89 (44-
260) 27 43 
Trabectedin - - - - - 6 (0.0) 1 (6) - - 
Dactinomycin - - - - - 72 (0.0) 12 (72) - - 
Doxorubicin 26 (0.2) 6 (0.0) 14 (0.1) 27 (0.1) 32 (0.1) 88 (0.0) 32 (6-88) 17 30 
Daunorubicin - - 15 (0.1) - 11 (0.0) - 4 (11-15) 1 - 
Epirubicin 87 (0.7) 95 (0.7) 70 (0.6) 96 (0.5) 61 (0.1) 44 (0.0) 76 (44-96) 18 41 
Idarubicin <1 - 1 (0.0) - 1 (0.0) - <1 (<1-1) <1 - 
Mitoxantrone <1 - 1 (0.0) - <1 - <1 (<1-1) <1 - 
Bleomycin 1 (0.0) 4 (0.0) 2 (0.0) <1 2 (0.0) 7 (0.0) 3 (<1 -4) 1 - 
Mitomycin C 16 (0.1) <1 11 (0.1) 13 (0.1) 3 (0.0) <1 8 (<1-16) 3 9 
Cisplatin 
45 (0.3) 190 (1.3) 39 (0.3) 43 (0.2) 16 (0.0) 370 (0.0) 
117 (16-
370) 23 67 
Carboplatin 
320 (2.4) 950 (6.7) 540 (4.5) 600 (3.3) 15 (0.0) 2800 (0.3) 
871 (15-
2800) 84 330 
Oxaliplatin 
96 (0.7) 130 (0.9) 110 (0.9) 89 (0.5) 74 (0.1) 510 (0.1) 
168 (74-
510) 33 64 
Procarbazine 24 (0.2) - - - 3 (0.0) 120 (0.0) 25 (3-120) 35 - 
Rituximab 
- 120 (0.8) 320 (2.7) - 310 (0.6) 18 (0.0) 
128 (18-
320) 72 - 
Trastuzumab 
250 (1.9) 370 (2.6) 160 (1.3) 260 (1.4) - 2000 (0.2) 
507 (160-
2000) 56 - 
Alemtuzumab - - - - 30 (0.1) - 5 (30) - - 
Cetuximab 
17 (0.1) 110 (0.8) 57 (0.5) - - 270 (0.0) 
76 (17-
270) 55 - 
“-” = not recorded 
1 Calculated using the average dose (mg) from NW hospital survey 
2 Comprising of Furness general hospital, Royal Lancaster Infirmary, Westmorland general hospital, Queen Victoria hospital, Ulverston 
community health centre. Population served 363,000 
3 Comprising of Royal Preston hospital (Rosemere cancer foundation) and Chorley and South Ribble hospital. Population served 390,000 
4 Comprising of Blackpool Victoria hospital, Clifton hospital, Fleetwood hospital and three elderly rehabilitation hospitals. Population served 
330,000 
5 Comprising of Burnley general hospital, Royal Blackburn hospital and Inpatient rehabilitation services are also provided at Pendle community 
hospital and the Rakehead unit at Burnley general hospital. Outpatient and diagnostic services are also provided at the Accrington Victoria, 
Clitheroe hospital, Rossendale and St Peters Primary health care centre’s. Population served 500,000 
6 Comprising of NHS Trafford (Trafford general hospital host to the Trafford Macmillan care centre); Bolton NHS Foundation trust (Royal 
Bolton hospital); Salford Royal NHS Foundation trust (Salford Royal hospital); Mid Cheshire hospitals NHS foundation trust (Leighton hospital, 
Victoria Infirmary and Elmhurst intermediate care centre); Wrightington, Wigan and Leigh NHS foundation trust (Royal Albert Edward 
Infirmary, Leigh Infirmary, Wrightington hospital and Thomas Linacre centre (provides the majority of out-patient services for the Trust). 
Population served 1,463,000 
7 Comprising of outpatient clinics at Linda McCartney centre (Royal Liverpool University hospital), the Countess of Chester, Southport hospital, 
Halton general hospital, Aintree University hospital, Broadgreen hospital and The Liverpool Woman’s. Population served 2,300,000 
  
Table S2: Average urinary excretion rates of the unchanged parent drug 
% of administered drug excreted (i.e. not metabolized) 
<5% 5-15% 15-25% 25-45% 45-75% >75% 
Chlorambuci
l1, 2, 3, 4 [1] 
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1, 2 [8] 
Topotecan















ate2, 3  [29] 
Pemetrexe
d1, 2, 3 [30] 
1 electronic Medicines Compendium (eMC) (http://www.medicines.org.uk/EMC) 
2 Product monograph 
(http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/default.htm) 
3 RxList (http://www.rxlist.com/script/main/hp.asp) 
4 Drugs.com (http://www.drugs.com/) 
5 Ema (http://www.ema.europa.eu/ema/) 
6ToxNet (http://toxnet.nlm.nih.gov/) 
*** No available data (Urinary excretion data was not available for six L01X 
anticancer drugs) 
  
Table S3: Physiochemical properties of selected cytotoxic drugs and their classification according to the Anatomical Therapeutic Classification 
(ATC) system. 















L01AA01 Cyclophosphamide 2.84, 6.00 [31, 32] Neutral Acid [32] 0.63  44 3 4.00E+04 
L01BC06 Capecitabine 8.8 [33] Neutral Acid 0.96*  8 3 8.23E+02 
L01BC02 5-Fluorouracil 7.6-8.0, 13.0 [32-34] Neutral Acid [32]  -0.93  4 3 1.11E+04 
L01XX05 Hydroxyurea 10.6* Neutral Acid -1.27  3 3 7.91E+04 
L01XE01 Imatinib 8.07, 3.73, 2.56, 1.52* Positive Base  0.19 16 3 6.48E+01 
L01BA01 Methotrexate  3.80, 4.8, 5.6 [33] Negative Acid  -1.41 20 3 4.98E+03 
L01XA02 Carboplatin 0.24, 3.55*  Base -1.78 0.01 891 [35]   
L01BC05 Gemcitabine 3.6 [34] Neutral Base -1.24  1 3 1.53E+046
L01CB01 Etoposide 9.8 [36] Neutral Acid 0.60  19 3 5.87E+01 
L01AA05 Ifosfamide 1.45-4.0 [31, 32] Neutral Base [32] 0.86  51 3 3.78E+03 
L01AX04 Dacarbazine 4.42* Neutral Base -0.24  15 10 4.22E+03 
L01AB02 Treosulfan 12.36* Neutral Acid -2.09*  1 3 7.00E+048
L01XX23 Mitotane N/A Neutral N/A 6.11*  154882 4989 1.00E-01 
L01XE07 Lapatinib 3.80, 7.202* Positive Base  4.72 426580 1127 9.06E-02 
L01CD01 Paclitaxel 11.99 Neutral Zwitterion [32] 5.25  58884 750 1.07E-04 
L01AA03 Melphalan 1.83, 9.13 [37] Neutral Acid [38]  -0.52  14 3 2.71E+02 
L01AA09 Bendamustine  0.88, 4.17, 6.945 Negative Zwitterion/Acid  2.84 977 3 2.69E+01 
L01AD01 Carmustine 12.27* Neutral Acid 1.53  89 5 1.83E+03 
L01AX03 Temozolomide N/A [39] Neutral Base 1.15  29 3 1.81E+03 
L01BA04 Pemetrexed  3.6, 4.4 [33] Negative Acid  -2.43 60 3 1.84E+02 
L01BB02 Mercaptopurine 7.9 [40] Neutral Acid [40] 0.67 
[40] 
 40 3 
1.98E+04 
L01BB05 Fludarabine 3.2, 5.8* Negative Acid  -1.22 2 3 1.44E+04 
L01BC01 Cytarabine 4.2 [34] Neutral Base -2.15  1 3 8.66E+04 
L01BC03 Tegafur 7.981 Neutral Acid -0.27  6 3 3.64E+03 
L01BC07 Azacitidine 2-3 [41] Neutral Base -2.17  1 3 8.89E+04 
L01CA04 Vinorelbine 7.4, 5.4 [42, 43] Positive Base 4.72* 4.57 30200 604 9.86E-03 
L01CD02 Docetaxel 12.02* Neutral Acid 3.64*  27 65 5.17E-03 
L01DA01 Dactinomycin  8.06 [44] Neutral Acid 1.42*     
L01DB01 Doxorubicin 7.34, 8.3, 9.46 [31, 33, 
45] 
Positive Base [32]  -1.93 389 3 
5.34E+02 
L01DB02 Daunorubicin 8.4 [31, 45] Positive Base [32]  -0.14 490 1 1.23E+02 
L01DB03 Epirubicin 7.7 [31] Positive Base*  -0.30 372 4 6.25E+02 
L01DC01 Bleomycin 7.3 [46] Positive Base  -0.47    
L01DC03 Mitomycin C 3.2 Neutral Base -0.38  76 3 8.11E+03 




L01XA03 Oxaliplatin 7.35, 9.99*  Base -1.63 -1.42    
L01XB01 Procarbazine 6.8* Neutral Base -0.82*  18 3 8.32E+03 
L01XE03 Erlotinib 5.42* Neutral Base 2.96*  2188 42 9.97E+00 
L01XE04 Sunitinib 8.95* Positive Base  0.76 891 29 1.52E+01 
L01XE05 Sorafenib 11.55, 2.032* Neutral Base/Acid 4.39*  2884 366 2.14E-01 
L01XE08 Nilotinib 2.1, 5.41 Neutral Base 3.60  79433 110 3.90E-01 
L01XE11 Pazopanib 2.1, 6.4, 10.23 Neutral Base/Acid 3.38*  12023 79 2.32E+00 
L01XX14 Tretinoin 5.0* Negative Acid  4.30    
L01XX17 Topotecan 0.60, 6.99, 10.50 [48] Positive Base/Acid  -3.13 107 3 3.30E+02 
L01XX19 Irinotecan 8.1* Positive Base  3.24 2818 355 3.64E-02 
L01XX32 Bortezomib 13.82* Neutral Acid 1.47*  766 4 2.13E+02 
L01XX41 Eribulin 9.592 Positive Base  -0.34 1288 14 2.70E+00 
1 www.ema.europa.eu/docs/en_GB/.../WC500034398.pdf 
2 ACD properties calculator (http://www.chemicalize.org/structure) 
3 http://www.medicines.org.au/files/gwpvotri.pdf 
4 BCF predicted with EPI SUITE: linear relationship with kow does not hold for many compounds with high polarity (see text) 
5 http://www.faqs.org/patents/app/20090264488 
6 MSDS gemcitabine (http://ehs.lilly.com/msds/Gemzar.pdf) 




8 MSDS treosulfan (http://www.medac.de/medac_international/data/SDS/treosulfan_E.pdf) 
*From predicted data 
** Calculated as an average, with consideration to dastinib a similar compound to basic ionization 
  
Table S4: Degradative loss processes: biodegradation and hydrolysis 










Results Log kOH 
(L/mole.s)1 





Cyclophosphamide ZWT2  (OECD 
302B) 
























related to CP 
[51] 
AS incubation 1 90, 
900ng/L 
No degradation [52]  
Ifosfamide ZWT2 (OECD 
302B) 
42 51.7mg/L No degradation -7.397 Neg. Neg. 1.88 [53] 



















related to IF 
[51] 
Treosulfan CBT3 (OECD 
301D) 
40 5mg/L 30% 
degradation in 
the first 28 days 
(40% in 40 
days) 








10% in the first 
four days 
N/A N/A N/A 1.85 [50] 
Pemetrexed Ready 
biodegradability 
29 N/A 20% was 
released as CO2 
N/A <10% ( 
at 
50°C)4 
N/A 1.85 MSDS4 
Biodegradation 
(sludge) 


















days = ~10% 
N/A N/A N/A 1.85 [50]  
CBT3 (OECD 
301D) 











5-fluorouracil  CBT3 (OECD 
301D) 
28 and 40 9.02mg/L No degradation N/A N/A N/A 1.85 [55] 
ZWT2 (OECD 
302B) 




10 5, 10, 
20mg/L 
100±4% (15% 
after 1 day and a 
sharp increase 






AS incubation 50 50ug/L <60% removal [56] 
after 50 days  






















OECD 303A 3 10mg/L 38-92% 
biodegradation 
[3] 
Gemcitabine CBT3 (OECD 
301D) 
40 1660mg/L 45% 
Degradation 
N/A Neg.5 N/A 1.85 [55] 
ZWT2 (OECD 
302B)  





28  30% 
degradation 
MSDS5 
Capecitabine ZWT2 (OECD 
303B) 
28 N/A 58% 
degradation 
(15% removed 
in 7 days) 
N/A N/A N/A 1.85 [3] 
Like OECD 
302C 




in 14 days 
[3] 




in 28 days 












ZWT2 40 N/A 18% 
degradation 
[58] 

















Etoposide N/A N/A N/A N/A -2.689 0.01 0.11 1.86 N/A 





















in liquid phase). 
Degraded 
mainly due to 
adsorption to 
N/A N/A N/A 1.85 [57] 
sludge 
Epirubicin CBT3 (OECD 
301D) 
N/A 5mg/L No degradation N/A N/A N/A 1.85 [59] 
ZWT2 (OECD 
302B) 
N/A N/A Degraded, 








N/A N/A Eliminated in 
ZWT but not in 
CBT 
[57] 
Mitoxantron CBT3 (OECD 
301D) 
40 5mg/L No degradation N/A N/A N/A  [54] 
Mitomycin N/A N/A N/A N/A -2.218 0.03 0.33 1.85 N/A 
Cisplatin OECD screening 
test 








28 N/A 9-12%; not 
readily 
biodegradable 
N/A N/A N/A 1.85 MSDS6 
Topotecan N/A N/A N/A N/A -0.986 0.45 5.62 1.85 N/A 





Neg. – negligible  
N/A – not available 
AS – activated sludge 
STP – sewage treatment plant 
1 Second order rate constant estimated using the SPARC model 
(http://archemcalc.com/sparc/test/login.cfm?CFID=250050&CFTOKEN=79322869) 
2 ZWT - Zahn-Wellens Test (test for inherent biodegradability – OECD302) 
3 CBT – Closed Bottle Test (OECD 301) 
4 MSDS pemetrexed (http://ehs.lilly.com/msds/Alimta.pdf) 
5 MSDS gemcitabine (http://ehs.lilly.com/msds/Gemzar.pdf) 






Table S5: Consumption and predicted fate of anticancer drugs likely to be present in sewage effluent based on 2010-2012 consumption in NW 
England. Values assume excretion of the unchanged drug based on Table S2 (Supplementary information) and ‘best values’ for estimated 












 % of intact drug after 
STP biodegradation 4 




conc. (ng/L) 5 
Predicted river water 




77.51 40 21 8.4 98.1* 8.3 41.3 4.1 - Continuous diffusive discharge7
- Persistence in the environment confirmed (hospital effluents, 
STP wastewaters and surface waters) 
L01BC06*** 
Capecitabine 
357.00 183 3 5.4 85.0 4.6 23.1 2.3 - Pro-drug of 5-FU (may contribute to 5-FU load) 
- Continuous diffusive discharge7 
- No biodegradation studies: used a predicted biodegradation rate 
similar to 5-FU (85% loss) – at present this is highly uncertain.  
L01BC02*** 
Fluorouracil 
22.99 12 18 2.1 85.0 1.8 8.9 0.9 - No evidence of abiotic degradation is apparent.  
- 5-FU has only been detected in hospital effluents, presence in 
surface waters needs confirming.  
L01XX05*** 
Hydroxyurea 
64.00 33 58 18.8 5.0 0.9 4.7 0.5 - By far the most consumed anticancer drug8
- No biodegradation studies: model predictions possibly 
underestimate its loss, particularly when incubated with activated 
sludge.  
- Urease catalyses the hydrolysis of urea, it also catalyses the 
hydrolysis of HU.  
- Due to hydrolysis the environmental persistence of this 
chemical is likely to be low relative to other L01 drugs.  
- Presence in the environment needs confirming 
L01XE01*** 
Imatinib 
20.40 10 9 0.9 98.2* 0.9 4.6 0.5 - Concern for contamination of soils (if sludge is dispersed onto 
fields) and water phase. 
- Presence in the environment needs confirming 
L01BA01*** 
Methotrexate 
1.31 1 83 0.6 90.0 0.5 2.5 0.2 - Point discharge (Primarily used to treat inpatients and 
administered 7days/week). Diffusive discharge (outpatient 
clinics) 
- Consumption underestimated8 
- Methotrexate not marked for environmental concern in other 
studies [ref] (removal rate of 95%), however, only 10% was 
removed in first four days akin to incubation time at STPs 
- Confirmed detection in sewage effluent at 12.9ng/L 
L01XA02*** 
Carboplatin 
5.23 3 54 1.4 30.0 0.4 2.2 0.2 - No other biodegradation studies are available for carboplatin 
and this assessment is based on the results from a pilot membrane 
bioreactor system [ref].  
L01BC05*** 
Gemcitabine 
12.97 7 8 0.5 70.0 0.4 1.8 0.2 - Persistence in the environment confirmed ( hospital effluents, 
STP wastewaters and surface waters) 
L01CB01*** 
Etoposide 
1.23 1 43 0.3 98.1* 0.3 1.3 0.1 - No biodegradation data 
- Persistence in the environment confirmed ( hospital effluents 
and STP wastewaters) 
L01XA03 
Oxaliplatin 
1.01 1 40 0.2 100.0** 0.2 1.0 0.1  
L01AA06*** 
Ifosfamide 
1.27 1 26 0.2 98.1* 0.2 0.8 0.1 - Point discharge (used to treat inpatients and administered 
7days/week). Continuous diffusive discharge7 
- Persistence in the environment confirmed ( hospital effluents 
and STP wastewaters and surface waters) 
L01AX04*** 
Dacarbazine 
0.75 0 36 0.1 98.2* 0.1 0.7 0.1 - 58% increased consumption from 2004 to 2008 [ref].  
- No biodegradation data available  
- Presence in the environment needs confirming 
L01AB02*** 
Treosulfan 
1.56 1 22 0.2 70.0 0.1 0.6 0.1 - Administered at high doses (1-5g) 
- Expect periodic detection or detection near hospitals that utilise 
this specialist chemotherapy.  
L01XA01 
Cisplatin 
0.70 0 33 0.1 98.2* 0.1 0.6 0.1  
L01XE03 
Erlotinib 
4.14 2 6 0.1 94.6* 0.1 0.6 0.1  
L01BC01 
Cytarabine 
1.98 1 10 0.1 90.0 0.1 0.5 0.0  
L01BA04 
Pemetrexed 
1.49 1 80 0.6 10.0 0.1 0.3 0.0  
L01XE04 
Sunitinib 
0.70 0 16 0.1 98.1* 0.1 0.3 0.0  
L01XX19 
Irinotecan 
0.56 0 16 0.0 91.7* 0.0 0.2 0.0  
L01AX03 
Temozolomide 
1.02 1 7 0.0 98.1* 0.0 0.2 0.0  
L01BC07 
Azacitidine 
0.07 0 68 0.0 98.2* 0.0 0.1 0.0  
L01DB03 
Epirubicin 
0.45 0 11 0.0 98.2* 0.0 0.1 0.0  
L01CD02 
Docetaxel 
0.53 0 7 0.0 83.4* 0.0 0.1 0.0  
L01BC03 
Tegafur 
0.12 0 20 0.0 98.2* 0.0 0.1 0.0  
L01DB01 
Doxorubicin 
0.19 0 14 0.0 80.0 0.0 0.1 0.0  
L01XX23**** 
Mitotane 
4.50 2 6 0.1 7.4* 0.0 0.1 0.0 - High dose (2-10g/day) only used at specialist hospitals 
- High bioaccumulation potential (log Koc > 5) 
L01XE07**** 
Lapatinib 
4.60 2 1 0.0 33.1* 0.0 0.1 0.0 - 92% of lapatinib seen in fecal excretion   
- High bioaccumulation potential (log Koc > 5) 
- 116% increased consumption from 2004 to 2008 [ref].  
L01AA09 
Bendamustine 
0.09 0 20 0.0 95.5* 0.0 0.0 0.0  
L01XB01 
Procarbazine 
0.15 0 11 0.0 98.2* 0.0 0.0 0.0  
L01CA04 
Vinorelbine 
0.30 0 13 0.0 33.1* 0.0 0.0 0.0  
L01DA01 
Dactinomycin 
0.07 0 17 0.0 100.0** 0.0 0.0 0.0  
L01BB05 
Fludarabine 
0.04 0 34 0.0 98.2* 0.0 0.0 0.0  
L01XE08 
Nilotinib 
0.57 0 2 0.0 84.5* 0.0 0.0 0.0  
L01DC01 
Bleomycin 
0.02 0 62 0.0 100.0** 0.0 0.0 0.0  
L01XX17 
Topotecan 
0.03 0 33 0.0 98.2* 0.0 0.0 0.0  
L01CD01**** 
Paclitaxel 
0.86 0 7 0.0 15.8* 0.0 0.0 0.0 - 61% of paclitaxel seen in fecal excretion   
- High bioaccumulation potential (log Koc > 5) 
L01XX14 
Tretinoin 
0.02 0 63 0.0 54.5* 0.0 0.0 0.0  
L01DB02 
Daunorubicin 
0.03 0 25 0.0 98.2* 0.0 0.0 0.0  
L01XX41 
Eribulin 
0.06 0 9 0.0 98.2* 0.0 0.0 0.0  
L01XE05 
Sorafenib 
10.28 5 0 0.0 49.9* 0.0 0.0 0.0  
L01XX32 
Bortezomib 
0.00 0 100 0.0 98.0* 0.0 0.0 0.0  
L01DC03 
Mitomycin 
0.04 0 10 0.0 98.2* 0.0 0.0 0.0  
L01AA03 
Melphalan 
0.02 0 20 0.0 98.2* 0.0 0.0 0.0  
L01AD01 
Carmustine 
0.01 0 57 0.0 98.0* 0.0 0.0 0.0  
L01XE11 
Pazopanib 
0.05 0 4 0.0 89.4* 0.0 0.0 0.0  
L01BB02 
Mitoxantrone 
0.00 0 7 0.0 100.0** 0.0 0.0 0.0  
1 Consumption total of NW survey 
2 Based on NW population of 5,346,000 from the populations each hospital serves 
3 Mean excretion rate taken from n clinical studies  
4 Estimated from EPISUITE biowin model or from biodegradation data table 4. Predictions based on literature values are shown with an asterisk. 
Where no EPISUITE prediction or literature value could be obtained it was presumed that 100% of the drug remained intact.  
5 200L/head dilution expected in STP [12] 
6 Further 10-fold dilution in the river [12]  
7 Communication with Blackpool Victoria hospital confirmed that treatments are more likely to commence during outpatients clinics (Mon-Fri), 
however, predominantly consumed by oral ingestion within the patients’ own home) 
8 Used in another ATC class 
* Predicted from EPISUITE 
** No rate available  
*** Priority chemical in surface water 
**** Priority chemical in soil 
 
  
Figure S1: Box and whisker plot of log Kow values for a wide number of anticancer drugs. For each chemical the Kow values were obtained from 
the literature (i.e. empirically observed) or calculated (n=1-22)
 
Recommended log Kow based on the most reliable data sources with consideration of Dow for ionisable compounds 
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